Source comparison
CJC-1295 vs MK-677 Which Better Comparison: Half-Life and Dosing Protocols
CJC-1295 with DAC has a terminal half-life of 6–8 days, meaning a single subcutaneous injection maintains therapeutic plasma levels for nearly a week. Standard research dosing protocols use 1–2mg administered once weekly or biweekly. The extended half-life all
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC has a terminal half-life of 6–8 days, meaning a single subcutaneous injection maintains therapeutic plasma levels for nearly a week. Standard research dosing protocols use 1–2mg administered once weekly or biweekly. The extended half-life allows the compound to be present during multiple endogenous GH pulse events without requiring timed administration. Researchers typically reconstitute lyophilised CJC-1295 with bacteriostatic water at concentrations of 2mg/mL, refrigerate at 2–8°C, and use within 28 days post-reconstitution.
- MK-677 has a much shorter half-life of 4–6 hours, requiring daily oral dosing to maintain stable plasma concentrations. Research protocols commonly use 12.5–25mg taken once daily, typically in the evening to align with natural nocturnal GH peaks and mitigate daytime appetite stimulation. MK-677 is orally bioavailable and stable at room temperature in capsule form, eliminating cold-chain storage requirements. Missing a dose results in a rapid return to baseline GH levels within 12–18 hours.
- The dosing flexibility of CJC-1295 makes it logistically simpler for long-term research models, while MK-677's daily administration allows tighter control over GH exposure windows.